15th Swiss Course on Medicinal Chemistry 2024
Leysin Switzerland
Leysin Switzerland
13.-18. October 2024, Alpine Classic Hotel
Program
Sunday, October 13, 2024
16.00
Course check in
18.00
Welcome and Conference Opening Dinner
20.00
Welcome, housekeeping
Introduction into program and tutorials
Intro lecture by Gerhard Müller
Introduction into program and tutorials
Intro lecture by Gerhard Müller
20.15
Gerhard Müller, SpiroChem
«Medicinal Chemistry, a personal View»
Monday, October 14, 2024
08.00
David Wilson, AstraZeneca
«Progress in Solving the 'Druggability' Challenges of Transformative Oncology Targets»
09.00
Jean-Louis Reymond, University of Bern
«Chemical Space for Drug Discovery»
10.00
Coffee Break
10.30
Pat Walters, Chief Data Officer, Relay Therapeutics
«Critical Assessment of AI in Drug Discovery 1»
11.30
Pat Walters, Chief Data Officer, Relay Therapeutics
«Critical Assessment of AI in Drug Discovery 2»
12.30
Lunch
14.00
Matthias van Woensel, Droia Ventures
«An Introduction to Venture Capital and Its Role in the Ecosystem»
15.15
J. Veerman, ZoBio / M. Carneiro, ZoBio
«Discovery and Optimization of Bromodomain Inhibitors»
Q. Lefebvre, SpiroChem / D. Pierrot, SpiroChem
«Case Studies on Accessing 3D Chemical Space by Isosteric Replacement»
K. Ritter, University of Tübingen / L. van Berkom, Symeres
«Designing a new class of Anti-cancer Compounds - Interrupted Case Studies of the Development of PARP Inhibitors»
N. Meanwell, Freelance Distinguished Professor
«Molecular Metaphors in Drug Design: A View Through the Lens of Phenyl Ring Mimetics»
M. Whittaker, Ebryl Ltd. / M. Mazanetz, Novadata Solutions Ltd.
«Fragment Based Lead Generation»
J. Viklund, J. Freeman and F.Milikovic, Astra Zeneca
«Fragment- and Structure-Based Drug Design»
18.00
Maria Duca, Université Côte d'Azur
«Targeting Non-coding RNAs Using Synthetic Small Molecules»
19.00
Tilly Bingham, Cumulus Oncology
«GPCRs, the Druggable Target Class "Gift That Keeps on Giving"!»
20.00
Dinner
Tuesday, October 15, 2024
08.00
Kirsten McAuley, University of Dundee
«Targeted Protein Degradation and Bifuncional Molecules (PROTACs and Beyond)»
09.00
Agnieszka Konopacka, ICR The Institute for Cancer Research Centre for Protein Degradation
«Applying Chemical Biology and Genetic Strategies for TPD Drug Discovery»
10.00
Coffee Break
10.30
Katerina Leftheris, CSO, Vilya Biotech
«Rediscoverying Macrocycles as a Modality in Drug Discovery»
11.30
Martina Petrovic, FireFly Research
«Medicinal Chemistry Around Macrocycles»
12.30
Lunch
14.00
Adrian Whitty, Professor, Boston University
«Macrocycles and Other «Beyond Rule-of-Five» Chemotypes»
15.15
J. Veerman, ZoBio / M. Carneiro, ZoBio
«Discovery and Optimization of Bromodomain Inhibitors»
Q. Lefebvre, SpiroChem / D. Pierrot, SpiroChem
«Case Studies on Accessing 3D Chemical Space by Isosteric Replacement»
K. Ritter, University of Tübingen / L. van Berkom, Symeres
«Designing a New Class of Anti-cancer Compounds - Interrupted Case Studies»
N. Meanwell, Freelance Distinguished Professor
«Molecular Metaphors in Drug Design: A View Through the Lens of Phenyl Ring Mimetics»
M. Whittaker, Ebryl Ltd. / M. Mazanetz, Novadata Solutions Ltd.
«Fragment Based Lead Generation»
J. Viklund, J. Freeman and F. Miljkovic, Astra Zeneca
«Fragment- and Structure-Based Drug Design»
Wednesday, October 16, 2024
08.00
Dorothea Gruber, Tolremo Therapeutics
«From the Lab to the Clinic: Development of TT125-802»
09.00
Gerhard Müller, SpiroChem
«The Kinase - Phosphatase Mystery: Medicinal Chemistry Under the Lamppost»
10.00
Coffee Break
10.30
Edmund Hoppe, Boehringer-Ingelheim
«Relevance and Application of ADME and PK Data 1»
11.30
Edmund Hoppe, Boehringer-Ingelheim
«Relevance and Application of ADME and PK Data 2»
12.30
Lunch
Thursday, October 17, 2024
08.00
Chun-wa Chung, Head Structural and Biophysical Sciences, GSK R&D
«The Application of Biophysical Methods in Drug Discovery»
09.00
Gerhard Klebe, Marburg University
«How Thermodynamics Can Help Understand Protein-ligand Binding in Medicinal Chemistry»
10.00
Coffee Break
10.30
Peter Tonge, Stony Brook University
«Kinetic Selectivity - A Missed Opportunity in Drug Discovery?»
11.30
Stephan Theisgen, Senior Scientist, ZoBio
«NMR in Drug Discovery - an Underestimated Biophysics Area»
12.30
Lunch
14.30
J. Veerman, ZoBio / M. Carneiro, ZoBio
«Discovery and Optimization of Bromodomain Inhibitors»
Q. Lefebvre, SpiroChem / D. Pierrot, SpiroChem
«Case Studies on Accessing 3D Chemical Space by Isosteric Replacement»
K. Ritter, University of Tübingen / L. van Berkom, Symeres
«Designing a new Class of Anti-cancer Compounds - Interrupted Case Studies»
N. Meanwell, Freelance Distinguished Professor
«Molecular Metaphors in Drug Design: A View Through the Lens of Phenyl Ring Mimetics»
M. Whittaker, Ebryl Ltd. / M. Mazanetz, Novadata Solutions Ltd.
«Fragment Based Lead Generation»
J. Viklund, J. Freeman and F. Miljkovic, Astra Zeneca
«Fragment- and Structure-Based Drug Design»
17.00
Coffee Break
17.30
Steven Richards, Vice President Chemistry, Ambagon Therapeutics
«Covalency in Drug Discovery»
Friday, October 18, 2024
08.00
Andrew Mortlock, Astellas Pharma
«Medicinal Chemistry and the Battle Against Prostate Cancer»
09.00
Eda Canales, Gilead Sciences
«Lenacapavir, a First-in-class Long-Acting HIV Capsid Inhibitor»
10.00
Nicholas Meanwell, Distinguished Professor, The Baruch S. Blumberg Institute, Doylestown, PA Adjunct Professor, Department of Medicinal Chemistry, School of Pharmacy, U. Michigan, Ann Arbor, MI Adjunct Professor, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ Principal, NuArq MedChem Consulting LLC
«Inhibitors of HIV-1 Maturation»
11.00
Coffee Break
11.30
Gerhard Müller, SpiroChem
concluding remarks
11.45
Lunch and End of the course